103
Participants
Start Date
February 22, 2018
Primary Completion Date
June 28, 2024
Study Completion Date
December 31, 2025
Nivolumab
Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).
Temozolomide
Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
Prince of Wales Hospital, Randwick
Chris O'Brien Lifehouse, Camperdown
Royal North Shore Hospital, Saint Leonards
Gosford Hospital, Gosford
Newcastle Private Hospital, New Lambton Heights
Port Macquarie Hospital, Port Macquarie
Wollongong Hospital, Wollongong
Campbelltown Hospital, Campbelltown
Peter MacCallum Cancer Centre, Melbourne
Austin Hospital, Heidelberg
Epworth Healthcare, Richmond
Monash Medical Centre, Clayton
Royal Brisbane and Women's Hospital, Herston
Icon Cancer Centre, South Brisbane
Princess Alexandra Hospital, Woolloongabba
Royal Adelaide Hospital, Adelaide
Flinders Medical Centre, Bedford Park
Sir Charles Gairdner Hospital, Nedlands
Royal Hobart Hospital, Hobart
Duke University Medical Center, Durham
Cooperative Trials Group for Neuro-Oncology
UNKNOWN
University of Sydney
OTHER